Chorismate synthase: An attractive target for drug development against orphan diseases

The increase in incidence of infectious diseases worldwide, particularly in developing countries, is worrying. Each year, 14 million people are killed by infectious diseases, mainly HIV/AIDS, respiratory infections, malaria and tuberculosis. Despite the great burden in the poor countries, drug discovery to treat tropical diseases has come to a standstill. There is no interest by the pharmaceutical industry in drug development against the major diseases of the poor countries, since the financial return cannot be guaranteed. This has created an urgent need for new therapeutics to neglected diseases. A possible approach has been the exploitation of the inhibition of unique targets, vital to the pathogen such as the shikimate pathway enzymes, which are present in bacteria, fungi and apicomplexan parasites but are absent in mammals. The chorismate synthase (CS) catalyses the seventh step in this pathway, the conversion of 5-enolpyruvylshikimate-3-phosphate to chorismate. The strict requirement for a reduced flavin mononucleotide and the anti 1,4 elimination are both unusual aspects which make CS reaction unique among flavin-dependent enzymes, representing an important target for the chemotherapeutic agents development. In this review we present the main biochemical features of CS from bacterial and fungal sources and their difference from the apicomplexan CS. The CS mechanisms proposed are discussed and compared with structural data. The CS structures of some organisms are compared and their distinct features analyzed. Some known CS inhibitors are presented and the main characteristics are discussed. The structural and kinetics data reviewed here can be useful for the design of inhibitors. © 2007 Bentham Science Publishers Ltd.

Arzneimittel für seltene Krankheiten (orphan drugs) : Das schweizerische Heilmittelrecht im Vergleich mit der orphan drug Regulierung der EU

Arzneimittel für seltene Krankheiten (orphan drugs) lassen sich unter normalen Marktbedingungen kaum kostendeckend erforschen, entwickeln und vermarkten, was zu einem Mangel an geeigneten Therapien und zugelassenen Arzneimitteln für seltene Krankheiten führt. Um den fortdauernden Ausschluss von betroffenen Patienten vom medizinischen Fortschritt zu verhindern und die Defizite in der Erforschung und Entwicklung von orphan drugs zu beseitigen, schuf die Europäische Union – nach US-amerikanischem Vorbild – ein Anreizsystem. Der vorliegende Beitrag erläutert die regulatorischen Rahmenbedingungen für orphan drugs in der EU und zeigt auf, dass die Schweiz in der Schaffung günstiger Rahmenbedingungen für Patientinnen und Patienten, die an einer seltenen Krankheit leiden, anderen Ländern um Jahre hinter her hinkt, sich aber allmählich etwas tut.

The causes of illegal drug industry growth in the Andes, Anti-Drug Policies and their effectiveness

.

Advances in sickle cell disease treatment: From drug discovery until the patient monitoring

Sickle Cell Disease (SCD) is one of the most prevalent hematological diseases in the world. Despite the immense progress in molecular knowledge about SCD in last years few therapeutical sources are currently available. Nowadays the treatment is performed mainly with drugs such as hydroxyurea or other fetal hemoglobin inducers and chelating agents. This review summarizes current knowledge about the treatment and the advancements in drug design in order to discover more effective and safe drugs. Patient monitoring methods in SCD are also discussed. © 2011 Bentham Science Publishers Ltd.

Orphan drugs and paediatric medicinal products

While the safety and availability of medicinal products for the majority of adult patients has steadily improved in recent decades, for children and people suffering from rare diseases (orphan diseases) there is a lack of approved medicinal products for these patient populations. Since the research and development of medicinal products is associated with high costs, the costs for paediatric medicinal products and medicines for rare diseases (orphan drugs) may barely be covered under normal market conditions due to the small patient populations. In order to prevent the continued exclusion of children and persons suffering from rare diseases from medical progress and to eliminate the deficits in the research and development of medicinal products for these patient groups, the European Union created, along the lines of the U.S. model, a system of incentives and constraints. Since 2000, under Regulation (EC) No. 141/2000 (Orphan Drug Regulation) there has been an incentive system to encourage the research and development of orphan drugs. With the goal of improving the health of children in Europe, Regulation (EC) No. 1901/2006 (Paediatric Regulation) combines economic incentives with the requirement to conduct paediatric studies. This article explains and comments on the specific regulatory framework for orphan drugs and paediatric medicinal products in the European Union.

Value Assessment of Orphan Drugs and Treatments for Rare Diseases

Thesis (Master's)--University of Washington, 2016-06

Evaluating health policy and legal responses : how to reduce barriers and improve access to orphan drugs for rare diseases in Canada

Abstract : Rare diseases are debilitating conditions often leading to severe clinical manifestations for affected patients. Orphan drugs have been developed to treat these rare diseases affecting a small number of individuals. Incentives in the legal framework aimed to recoup the research and development cost of orphan drugs for pharmaceutical companies have been implemented in the United States and the European Union. At the present time, Canada is still lacking a legal and policy framework for orphan drugs. Several problems at the federal and provincial levels remain: lack of research funds for rare diseases, discrepancies on orphan drug policies between provinces, difficulties to access and reimburse these high price drugs. Recommendations and measures are proposed, such as a pan-Canadian (national) scientific committee to establish evidence-based guidelines for patients to access orphan drugs uniformly in all provinces with a disease specific registry, a formal agreement for a centralized Canadian public funding reimbursement procedure, and increasing the role of “guardian” for prices by the Patented Medicines Review Board in Canada. These recommendations and measures will be beneficial for the implementation of a policy framework for orphan drugs in Canada.

Cuestiones controvertidas en evaluación económica (III). Intervenciones sanitarias en tres situaciones especiales: enfermedades raras, tratamientos al final de la vida y externalidades en las evaluaciones.

The development of the economic evaluation of health care interventions has become a support tool in making decisions on pricing and reimbursement of new health interventions. The increasingly extensive application of these techniques has led to the identification of particular situations in which, for various reasons, it may be reasonable to take into account special considerations when applying the general principles of economic evaluation. In this article, which closes a series of three, we will discuss, using the Metaplan technique, about the economic evaluation of health interventions in special situations such as rare diseases and end of life treatments, as well as consideration of externalities in assessments, finally pointing out some research areas to solve the main problems identified in these fields.

Sustainable drugs and global health care

Each day, Earth's finite resources are being depleted for energy, for material goods, for transportation, for housing, and for drugs. As we evolve scientifically and technologically, and as the population of the world rapidly approaches 7 billion and beyond, among the many issues with which we are faced is the continued availability of drugs for future global health care. Medicinal agents are primarily derived from two sources, synthetic and natural, or in some cases, as semi-synthetic compounds, a mixture of the two. For the developed world, efforts have been initiated to make drug production "greener", with milder reagents, shorter reaction times, and more efficient processing, thereby using less energy, and reactions which are more atom efficient, and generate fewer by-products. However, most of the world's population uses plants, in either crude or extract form, for their primary health care. There is relatively little discussion as yet, about the long term effects of the current, non-sustainable harvesting methods for medicinal plants from the wild, which are depleting these critical resources without concurrent initiatives to commercialize their cultivation. To meet future public health care needs, a paradigm shift is required in order to adopt new approaches using contemporary technology which will result in drugs being regarded as a sustainable commodity, irrespective of their source. In this presentation, several approaches to enhancing and sustaining the availability of drugs, both synthetic and natural, will be discussed, including the use of vegetables as chemical reagents, and the deployment of integrated strategies involving information systems, biotechnology, nanotechnology, and detection techniques for the development of medicinal plants with enhanced levels of bioactive agents.

Análisis de la política prohibicionista de Estados Unidos hacia Colombia en el tema de las drogas ilícitas

El análisis de la política exterior de EE.UU hacia Colombia en el tema de las drogas ilícitas, revela en qué consiste el prohibicionismo y cuáles han sido sus resultados en Colombia y los países vecinos.

Análisis de los componentes de la cadena de suministro y su relación con el desempeño superior de la organización en el sector manufacturero

En este documento se evidencia como el desempeño organizacional de una empresa, entendido como el rendimiento superior de la misma, se ve modificado por las prácticas o metodologías utilizadas, aplicadas e integradas a cada uno de los componentes de la Cadena de suministros. Es así que el propósito principal es demostrar cual es la relación entre los componentes de la Cadena de Suministros y su gestión sobre los rendimientos económicos de la empresa. De esa manera se encontraron múltiples actividades que toman lugar en los procesos característicos de cada uno de los componentes de la cadena de suministros y que al final nos presentan una variabilidad sobre los rendimientos de la empresa. Cabe recalcar que la investigación se realizó con respecto a empresas pertenecientes al sector manufacturero y abarca una buena parte de este. La importancia que tiene la investigación, es el haber entregado como resultado, el conocimiento sobre algunas de las practicas más utilizadas en el sector en cada uno de sus componentes, lo cual hace de la Cadena de suministros, un factor por excelencia para ser tratado e implementado con el fin de alcanzar mayores rendimientos económicos a nivel de empresa. En la investigación se utilizaron los casos de empresas reales tanto nacionales como internacionales y se encontraron situaciones claves que evidenciaban la hipótesis de la relación entre la cadena de suministros y el desempeño organizacional. Es por ello, que si bien es ahora cierto, que las actividades desarrolladas en los componentes de la Cadena de Suministros de las empresas influyen en el incremento de los rendimientos, es importante que las empresas conozcan de esta información para tener una idea de cómo desarrollar ventajas competitivas que los posicionen como empresa y les genere entonces mayores rendimientos, o por el contrario, les genere ahorros en costos y por ende altos beneficios y nuevas inversiones en prácticas que a la larga volverá a la empresa en un organismo eficientes y próspero.

A farmácia e a cosmética no século XIX em Portugal

Os cosméticos sempre estiveram presentes desde os primórdios da Humanidade, existindo actualmente uma enorme panóplia de produtos ao alcance dos consumidores. Desde sempre o homem se preocupou com a sua aparência e para tal utilizou os cosméticos como forma de realçar a sua beleza. Durante o século XIX a área dos cosméticos e da farmácia sofreu uma grande evolução devido à revolução industrial e ao aparecimento de novas tecnologias. No século XIX surgiram pela primeira vez métodos de eliminação de rugas, de embelezamento do rosto e na higiene deu-se importância aos banhos com a criação dos balneários públicos. A crescente procura de beleza levou à criação de produtos cosméticos diversos, alguns dos quais perigosos para a saúde, sendo este um dos pontos a abordar nesta tese. Os cosméticos serão abordados como um bem de luxo num país que vivia em extrema pobreza. Serão abordados outros pontos como a importância de produtos cosméticos estrangeiros e efectuar-se-á uma comparação entre um cosmético actual e um do século XIX. A Farmácia em Portugal sofreu profundas alterações no século XIX. A botica deu lugar à farmácia e a produção de medicamentos que anteriormente era feita artesanalmente, passou a ser feita industrialmente. A extinção das ordens religiosas em Portugal em 1834 foi crucial para o desenvolvimento das farmácias. O encerramento das farmácias dos mosteiros originou uma maior viabilização e abrangência territorial dos estabelecimentos privados. Este foi o momento na história da farmácia em Portugal que levou à formação do associativismo. O avanço da produção científica e da literatura técnico profissional que se verificava por toda a Europa também se repercutiu em Portugal. Como exemplo da Literatura Farmacêutica Portuguesa neste século temos a publicação do Codigo Pharmaceutico lusitano. Com o surgimento da era industrial e consequente aumento dos bens produzidos, aperfeiçoou-se a técnica publicitária que deixou de ser unicamente informativa para ser mais persuasiva e agressiva levando o consumidor a comprar. Com esta tese de mestrado tenta-se demonstrar o impacto da revolução industrial no Farmacêutico em Portugal e avaliar a sua resposta às necessidades de mercado. O profissional de saúde deverá apreender rapidamente conhecimento de modo a não perder a sua identidade.

Crystal structure of isotibolone: a major degradation product of tibolone

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Social Panorama of Latin America 1999-2000

Includes bibliography